JAGSNPHARM - Reversal signA very positive reversal sign in JAGSNPHARM can be seen.
Taken support of 20EMA band and also support from RSI 50.
you can use marked SL and Target or do your own study and find one.
Do your own study and analysis and act accordingly.
Strictly follow Risk Reward management and strict SL is necess
7.89 INR
224.63 M INR
2.09 B INR
17.87 M
About JAGSONPAL PHARMACEUTICALS
Sector
Industry
CEO
Manish Gupta
Website
Headquarters
Gurugram
Founded
1978
ISIN
INE048B01035
FIGI
BBG000CTMHK8
Jagsonpal Pharmaceuticals Ltd. engages in the development and manufacture of intermediate drugs and pharmaceutical formulations. It offers portfolio of drugs focusing on the gynaecology, dermatology, paediatric, and orthopaedic segments. The company was founded by Jagmohan Singh Kochhar on August 17, 1978 and is headquartered in Gurugram, India.
52 Week High Breakout - Positional Trade - Long TermDisclaimer: I am not a Sebi registered adviser.
This Idea is publish purely for educational purpose only before investing in any stocks please take advise from your financial adviser.
52 Week Breakout. Stock has Crossed 52 week High. Keep in watch list. Buy above the high. Suitable for Positional T
Key Support & Resistance Breakout - Swing TradeDisclaimer: I am not a Sebi registered adviser.
This Idea is publish purely for educational purpose only before investing in any stocks please take advise from your financial adviser.
Key Support & Resistance Breakout. Stock has give Breakout of Resistance level. Keep in watch list. Buy above the h
#JAGSNPHARM Ready for a potential breakout !🌟PROS :
⭐️- Company is almost debt free.
⭐️-Company has delivered good profit growth of 35.2% CAGR over last 5 years
⭐️-Company has been maintaining a healthy dividend payout of 40.0%
⭐️-Company's working capital requirements have reduced from 46.6 days to 35.6 days
Technical View :
🌟- Base breako
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of JAGSNPHARM is 219.39 INR — it has increased by 4.11% in the past 24 hours. Watch JAGSONPAL PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange JAGSONPAL PHARMACEUTICALS stocks are traded under the ticker JAGSNPHARM.
JAGSNPHARM stock has risen by 6.32% compared to the previous week, the month change is a 5.22% rise, over the last year JAGSONPAL PHARMACEUTICALS has showed a 91.77% increase.
JAGSNPHARM reached its all-time high on Nov 29, 2024 with the price of 328.04 INR, and its all-time low was 2.40 INR and was reached on Oct 27, 2008. View more price dynamics on JAGSNPHARM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
JAGSNPHARM stock is 4.92% volatile and has beta coefficient of 1.55. Track JAGSONPAL PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is JAGSONPAL PHARMACEUTICALS there?
Today JAGSONPAL PHARMACEUTICALS has the market capitalization of 13.99 B, it has decreased by −6.98% over the last week.
Yes, you can track JAGSONPAL PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
JAGSNPHARM net income for the last quarter is 319.90 M INR, while the quarter before that showed 114.59 M INR of net income which accounts for 179.17% change. Track more JAGSONPAL PHARMACEUTICALS financial stats to get the full picture.
Yes, JAGSNPHARM dividends are paid annually. The last dividend per share was 5.00 INR. As of today, Dividend Yield (TTM)% is 0.95%. Tracking JAGSONPAL PHARMACEUTICALS dividends might help you take more informed decisions.
JAGSONPAL PHARMACEUTICALS dividend yield was 1.79% in 2023, and payout ratio reached 58.87%. The year before the numbers were 1.72% and 49.02% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 15, 2025, the company has 1.02 K employees. See our rating of the largest employees — is JAGSONPAL PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JAGSONPAL PHARMACEUTICALS EBITDA is 450.26 M INR, and current EBITDA margin is 11.35%. See more stats in JAGSONPAL PHARMACEUTICALS financial statements.
Like other stocks, JAGSNPHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JAGSONPAL PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JAGSONPAL PHARMACEUTICALS technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JAGSONPAL PHARMACEUTICALS stock shows the buy signal. See more of JAGSONPAL PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.